The Mallinckrodt Institute of Radiology at Washington University School of Medicine, St. Louis, MO is currently accepting applications for our ACGME-accredited Nuclear Medicine Residency Program for July 1, 2020, for applicants seeking a one-, two-, or three-year of residency/fellowship training in nuclear medicine.
The goal of this residency/fellowship is to train physicians and radiologists of diverse backgrounds to become the next generation of leaders in academic and clinical Nuclear Medicine. Our program provides comprehensive resident/fellow training in the basic sciences, clinical imaging, and radionuclide therapies as they relate to Nuclear Medicine. With the assistance of mentors, residents are encouraged to identify and take advantage of clinical, academic and research opportunities that will help to make them successful in their careers. Our program provides intensive clinical training in both adult and pediatric nuclear medicine. Residents/fellows gradually assume increased responsibility in the clinical service while always working closely with an attending physician who reviews every case with them. Although we emphasize diagnostic imaging, extensive experience is also provided in radioiodine therapy of hyperthyroidism and additional experience is provided in cancer therapy, primarily treatment of thyroid cancer. Therapeutic use of parenteral therapy (Lutathera®, Xofigo® and SIR-Spheres) also is included. Special features of the training program include a nuclear cardiac imaging service, clinical PET/CT and PET/MRI facilities, and a pediatric service. Residents are encouraged to participate in original research under faculty supervision.
Upon successful completion of the program, candidates will be eligible for the American Board of Nuclear Medicine examination.